Study of Decitabine and Tetrahydrouridine (THU) in Patients With Sickle Cell Disease
Status:
Completed
Trial end date:
2018-06-01
Target enrollment:
Participant gender:
Summary
The purposes of this study are to observe if oral tetrahydrouridine and decitabine can
increase fetal hemoglobin levels and improve the symptoms of sickle cell disease, and to
monitor how patient's bodies react to oral tetrahydrouridine and decitabine.